SAN DIEGO and SUZHOU, China, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company ...

IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

As global data traffic soars, transmitting information with light instead of electrical signals is becoming crucial for ...

Bicara Therapeutics (NASDAQ:BCAX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its ...

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

In January 2022, Garutadustat, the innovative, potentially best-in-class, oral PHD inhibitor was nominated as a preclinical ...

CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring Committee (DMC) meeting ...

Insilico Medicine (3696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of ...

Abstract: This paper represents the novel architecture, simulation, and characterization of Quadrature Phase Shift Keying (QPSK) modulation for the performance evaluation of Airborne Data Link using ...

Abstract: In response to the demand for high-speed communication and high-precision Sensing in 6G technology, this paper presents a differential chaotic phase-shifting keying waveform design scheme ...

Across the Middle East, leaders are navigating unprecedented transformation. As economies diversify and organizations race to localize talent, attract global expertise, and foster innovation, the ...